Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

BACKGROUND: Neutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically efficacious when administered early, decreasing hospitalization and mortality in patients with mild or moderate COVID-19. We investigated the effects of receiving mAbs (bamlanivimab alone and bamlanivimab and etesevim...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, Poorbaugh, Josh, Dougan, Michael, Chen, Peter, Gottlieb, Robert L., Huhn, Gregory, Beasley, Stephanie, Daniels, Montanea, Ngoc Vy Trinh, Thi, Crisp, Melissa, Freitas, Joshua Joaquin, Vaillancourt, Peter, Patel, Dipak R., Nirula, Ajay, Kallewaard, Nicole L., Higgs, Richard E., Benschop, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697104/
https://www.ncbi.nlm.nih.gov/pubmed/34956222
http://dx.doi.org/10.3389/fimmu.2021.790469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697104/
https://www.ncbi.nlm.nih.gov/pubmed/34956222
http://dx.doi.org/10.3389/fimmu.2021.790469

Ejemplares similares